_

5 Best Biotech Stocks Under $10 to Buy

Neha Gupta Sat, October 31, 2026 at 5:30 PM EDT 10 min read **

• ^GSPC

In this article we will present the 5 best biotech stocks under $10 to buy. For an expanded list, please see the 10 Best Biotech Stocks Under $10 to Buy**.

Biotechnology stocks have delivered strong gains in 2026, supported by encouraging clinical trial results, regulatory approvals, and growth in drug sales. Investors' appetite for high-growth companies has also edged higher, as depicted by the S&P 500 biotechnology sector gaining 31% year-to-date, in line with the Insider Monkey Billionaire Index gain. Advances in drug development for cancer and genetic disorders have also strengthened investor sentiment in the sector.

In addition to strong investor interest, a surge in merger and acquisition deals has also supported the rally. As major pharmaceutical companies seek to replenish their drug pipelines and offset revenue losses from patent expirations, many have turned to smaller firms developing promising therapies.

Deal activity has largely focused on companies developing treatments in obesity, immunology, inflammation, oncology, and rare diseases., deal-making is on course for a bumper year after hitting $84 billion in the first quarter as large drug makers look to boost their pipelines.

Deal-making continued to gain momentum in the first half of the year, with transactions totaling approximately $117.7 billion. Notable deals include Sun Pharmaceutical's $12.6 billion acquisition of Organon and Eli Lilly's $8.1 billion deal for Centessa Pharmaceutical.

According to Moody's, pharmaceutical companies had close to $175 billion in cash and free cash flow to pursue acquisitions. Meanwhile, smaller biotechnology firms have faced greater financing challenges in a high-interest-rate environment. That's because they rely on external financing while developing medicines, which can be expensive as interest rates rise.

Against this backdrop, initial public offering activity in the sector has also slowed. The slowdown comes as investors increasingly demand evidence of clinical progress and commercial potential before committing capital to newly listed businesses.

Some of the subsectors with the strongest growth outlook include oncology, where demand for cancer treatments and targeted therapies remains strong. Obesity and metabolic disease also present strong commercial opportunities. Goldman Sachs expects global obesity sales to increase 15% to $114 billion.

Artificial intelligence is another emerging growth driver given its potential to improve research productivity and identify promising drug candidates. Check out these popular hedge funds healthcare stocks benefiting from AI use in drug development.

** Story Continues Small biotechnology stocks have participated in the broader rally in 2026, but performance is highly uneven. Stocks trading below $10 may attract investors seeking exposure to emerging therapies and potential clinical or regulatory catalysts at relatively low share prices. Take a look at some of the cheap biotech stocks on valuation.

For investors, the most compelling candidates have credible clinical programs, enough cash to fund upcoming milestones, differentiated treatment candidates, and a realistic path to commercialization.

Our Methodology**

For this article, we used stock screeners to identify biotechnology stocks with market capitalizations above $1 billion. We then focused on stocks trading below $10 and popular among elite hedge funds in Q2 2026. From this group, we selected 10 stocks and ranked them in ascending order by the number of hedge funds holding stakes.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey's quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

5. Savara Inc. (NASDAQ:SVRA)

Number of Hedge Fund Holders: 36_

Market Capitalization as of October 27: $1.03 Billion

Share Price as of October 27: $4.86

Savara Inc. (NASDAQ:SVRA) is an emerging high-risk, high-reward investment opportunity as it advances its lead drug candidate, molgramostim inhalation solution, MOLBREEVI. The inhaled treatment is designed to address autoimmune pulmonary alveolar proteinosis (aPAP), a rare and potentially serious lung disease.

The US Food and Drug Administration (FDA) has accepted Savara's biologics license application (BLA) for MOLBREEVI, bringing the company closer to a potential regulatory decision. Approval would pave the way for commercialization and mark a significant milestone in Savara's transition from a clinical-stage biotechnology company to a commercial-stage rare disease business. What Does Wall Street Think About Savara?

Wall Street has also expressed confidence in theSavara Inc. (NASDAQ:SVRA)'s prospects. On October 7, JPMorgan initiated coverage of the stock with an Overweight rating and a $12 price target, citing the potential for MOLBREEVI approval in the United States, the United Kingdom, and the European Union to unlock substantial commercial opportunities. Savara ended the second quarter with $173 million in cash and cash equivalents, providing financial resources to support launch preparations and advance its commercialization strategy.

_ 5 Best Biotech Stocks Under $10 to Buy Photo from Iovance Biotherapeutics website

**Read Also: **Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections

Savara Inc. (NASDAQ:SVRA)'s edge as one of the best biotech stocks under 10 to buy hinges on MOLBREEVI becoming the first approved pharmacological treatment for autoimmune PAP. Regulatory approval would open the door to a commercial business built around an underserved rare respiratory disease. Positive clinical findings, regulatory applications in multiple markets, and cash reserves to support launch preparations provide the foundation for that opportunity.

4. Absci Corporation (NASDAQ:ABSI)

Number of Hedge Fund Holders: 39_

Market Capitalization as of October 27: $1.42 Billion

Share Price as of October 27: $8.25

Absci Corporation (NASDAQ:ABSI) has significantly outperformed the broader biotechnology sector in 2026, as investors increasingly recognize the potential of its artificial intelligence (AI)-powered drug discovery platform. A 180% plus year-to-date rally has propelled the stock higher.

Amid the blockbuster gains, Wall Street firms still see room for further upside, calling it one of the best biotech stocks under $10 to buy. KeyBanc reiterated a buy rating on the stock on October 16 and set a $20 price target, buoyed by progress in the company's clinical pipeline.

JPMorgan had also raised its price target to $15 from $14, on October 12, while maintaining an overweight rating. The hike came amid heightened focus on the company's generative AI-designed biologics platform. Is Absci still a Buy after explosive rally?

A key driver of investor interest is the company's ABS-201 program, which targets potential treatments for conditions including endometriosis and hair loss. Absci has also reported encouraging interim Phase 1 results for ABS-201 in human trials as a treatment for durable hair growth. Explore how Absci is pursuing the hair loss opportunity.

Beyond pipeline development, investor sentiment improved after Eli Lilly participated in the company's $100 million share offering. The investment provides additional capital to support the company's drug discovery efforts and clinical development programs.

Positive early clinical data, strategic partnership, and enthusiasm for AI-driven drug discovery help explain why Wall Street firms are overly bullish on Absci's long-term prospects.

3. Taysha Gene Therapies Inc. (NASDAQ:TSHA)

Number of Hedge Fund Holders: 41

Market Capitalization as of October 27: $1.38 Billion

Share Price as of October 27: $4.25

Taysha Gene Therapies Inc. (NASDAQ:TSHA) has retreated after a strong rally in 2025, with shares down about 19% in 2026. Despite the pullback, the company remains one of the best biotech stocks under $10 to buy, supported by encouraging clinical progress in its gene therapy pipeline, particularly TSHA-102.

On September 17, Wolfe Research reiterated an Outperform rating, citing potential of the company's pipeline. The company has already delivered positive trial results for the investigational treatment for Rett Syndrome. Pivotal studies have shown that the candidate drug could become a disease-modifying treatment for patients who currently lack an approved therapy.

Rett syndrome has substantial unmet medical needs, creating substantial commercial opportunities. Therefore, Taysha is facing a tremendous revenue opportunity with a candidate drug demonstrating meaningful, durable benefits.

Additionally, the company remains in a strong financial position, having completed a $230 million follow-on offering in the second quarter. It also had about $455.4 million in cash and cash equivalents to support potential commercial production if TSHA-102 receives FDA approval.

Encouraging clinical progress, a potentially meaningful commercial opportunity, and a strengthened balance sheet underline why Taysha stands out as one of the top biotech stocks. Here's how the stock stands out on valuation.

2. Nuvation Bio Inc. (NYSE:NUVB)

Number of Hedge Fund Holders: 42

Market Capitalization as of October 27: $1.60 Billion

Share Price as of October 27: $4.55

Nuvation Bio Inc. (NYSE:NUVB) has struggled in 2026, with its shares down more than 45% compared to a 31% gain for biotech stocks in the S&P 500. The big question now is whether it is still one of the best biotech stocks under $10 to buy as it develops its oncology portfolio.

The company's long-term prospects hinge on its three principal assets. IBTROZI (taletrectinib) is the company's FDA-approved treatment for non-small cell lung cancer. It is also the most near-term revenue driver. The company is also developing Safusidenib as an investigational IDH1 inhibitor for IDH1-mutant Glioma. What are analysts saying about Ibtrozi commercialization?

Wall Street is optimistic about its long-term prospects. Citi initiated coverage with a Buy rating and a $12 price target on September 30. It touted it as an emerging oncology leader given the commercialization progress, as safusidenib also offers new growth opportunities. Cantor Fitzgerald shares a similar view, having reiterated an Overweight rating and a $12 price target on August 21, as it expects Ibtrozi sales to peak at $965 million.

While Nuvation Bio Inc. (NYSE:NUVB) remains under pressure, financial results indicate the company is starting to generate meaningful product revenue. Net product revenues attributed to IBTROZI surged 25% quarter over quarter in the second quarter to $23.2 million, affirming continued adoption. Can Nuvation Stock bounce back?

While Nuvation Bio has underperformed in 2026, its declining share price does not undermine its long-term investment case. Commercial progress and safusidenib developments provide a credible foundation for a bullish long-term thesis.

1. Ocular Therapeutix (NASDAQ:OCUL)

Number of Hedge Fund Holders: 49

Market Capitalization as of October 27: $1.48 Billion

Share Price as of October 27: $6.72

Ocular Therapeutix Inc. (NASDAQ:OCUL) has struggled in 2026, with its shares down nearly 43% and underperforming the broader biotechnology sector, which has gained about 31%. Amid the selloff, UBS reiterated confidence in the company's long-term prospects on October 11, asserting why it is one of the best biotech stocks under $10 to buy.

The research firm initiated coverage with a Buy rating and a $14 price target on October 11. According to the research firm, the lead asset, AXPAXLI, for wet age-related macular degeneration (wet AMD) could unlock substantial value and generate up to $3.3 billion in sales by 2035.

The sentiment comes as the company increasingly positions the lead investigational treatment to provide sustained drug delivery and reduce the frequency of injections required to manage retinal disease. The company is targeting an NDA submission in the fourth quarter, a milestone that could bring the treatment closer to commercialization. Is the stock a Buy on NDA catalyst?

Similarly, Ocular Therapeutix Inc. (NASDAQ:OCUL) maintains a substantial cash position needed to support AXPAXLI commercial launch. It ended the second quarter with cash and cash equivalents of $600.2 million, up from $392.75 million in the same period last year.

Ocular Therapeutix's underperformance reflects growing competitive concerns, high clinical expectations, and persistent financial losses, not definitive evidence that AXPAXLI has failed. Therefore, the stock can offer substantial upside to investors who can tolerate clinical and financing risk. Explore why the stock is positioned for growth.

While we acknowledge the potential of OCUL to grow, we believe certain AI infrastructure stocks offer far stronger long-term potential at a much more attractive entry point. If you are looking for an AI stock more promising than OCUL that operates as a critical AI tollbooth and stands as the most important company in the world, check out our report about this must-own AI stock.

Click to continue reading and see the expanded list of the 10 Best Biotech Stocks Under $10 to Buy.

Disclosure: None.

Terms and Privacy Policy [Privacy Dashboard ](https://guce.yahoo.com/privacy-dashboard?